Study: Alzheimer's Drug for Medicare Patients Could Cost U.S. at Least $2B Annually
Wide coverage of Alzheimer's drug Leqembi would raise future costs for Medicare by at least $2 billion a year, according to a study led by University of California researchers.
Source: timesofsandiego.com